Patents by Inventor Nicolas Ortonne

Nicolas Ortonne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS
    Publication number: 20240175873
    Abstract: T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.
    Type: Application
    Filed: March 22, 2022
    Publication date: May 30, 2024
    Inventors: Armand BENSUSSAN, Jérôme GIUSTINIANI, Martine BAGOT, Adèle DE MASSON D'AUTUME, Nicolas ORTONNE, Maxime BATTISTELLA, Anne MARIE-CARDINE
  • KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS
    Publication number: 20180291102
    Abstract: The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma.
    Type: Application
    Filed: May 23, 2018
    Publication date: October 11, 2018
    Inventors: Philippe GAULARD, Nicolas ORTONNE, Anne MARIE-CARDINE, Armand BENSUSSAN
  • KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS
    Publication number: 20160130346
    Abstract: The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma.
    Type: Application
    Filed: May 28, 2014
    Publication date: May 12, 2016
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, UNIVERSITE PARIS DIDEROT - PARIS 7
    Inventors: Philippe GAULARD, Nicolas ORTONNE, Anne MARIE-CARDINE, Armand BENSUSSAN
  • USE OF SOLUBLE CD160 TO SUPPRESS IMMUNITY
    Publication number: 20100008932
    Abstract: Pharmaceutical composition including a soluble form of CD160 for treating an inflammatory condition involving an undesired immune response, such as tissue graft or organ rejection, and autoimmune diseases; in vitro method for screening an individual for the presence of an inflammatory condition such as infectious and autoimmune diseases, tissue graft and organ rejection, or the presence of a tumor or activated endothelial cells, or for monitoring therapy of an inflammatory condition such as an autoimmune disorder or a tissue or organ rejection, or a tumor during chemotherapy including treatment with an anti-angiogenic substance or antibody.
    Type: Application
    Filed: July 18, 2007
    Publication date: January 14, 2010
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Armand Bensussan, Laurence Boumsell, Nicolas Ortonne